BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 11, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited , received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include
-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $476.9 Million in 2018, Including $132.1 Million in the Fourth Quarter- -ADCETRIS Approved by FDA in Combination with Chemotherapy for Frontline CD30-Expressing PTCL- -Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic
BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 6, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time . The presentation will be webcast live and
BOTHELL, Wash. --(BUSINESS WIRE)--Jan. 22, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will
-North American Subgroup Analysis Trial Results Published in Clinical Cancer Research - -Data Consistent with ECHELON-1 Trial Outcome Showing Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma- BOTHELL, Wash.
BOTHELL, Wash. --(BUSINESS WIRE)--Dec. 19, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. Pacific Time . Both the presentation and question and answer session that
-Data Presented in Oral Session with Simultaneous Publication in The Lancet- -Randomized Phase 3 Clinical Trial Demonstrated ADCETRIS plus Chemotherapy Resulted in Superior Progression-Free Survival and Overall Survival Compared to a Standard of Care, CHOP- BOTHELL, Wash. & CAMBRIDGE, Mass.
-Data Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma- -Three-Year Progression-Free Survival Data Demonstrate ADCETRIS plus AVD Benefit of 83.1 Percent Compared to 76.0 Percent in ABVD Arm- -ADCETRIS in
-Initial Data Reported from Phase 2 Clinical Trial in Relapsed Primary Mediastinal Large B-Cell Lymphoma- -Results from Phase 1/2 Trial in Relapsed Hodgkin Lymphoma Continue to Support Combination Strategy- -Phase 2 Trial Evaluating Novel Combination Strategies in Children, Adolescents and Young
BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 26, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 3, 2018 during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, Calif. The program
